English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Caelyx (doxorubicin hydrochloride) – Summary of product characteristics - L01DB

Updated on site: 05-Oct-2017

Medication nameCaelyx
ATC CodeL01DB
Substancedoxorubicin hydrochloride
ManufacturerJanssen-Cilag International N.V.

1.NAME OF THE MEDICINAL PRODUCT

Caelyx 2 mg/ml concentrate for solution for infusion

2.QUALITATIVE AND QUANTITATIVE COMPOSITION

One ml of Caelyx contains 2 mg doxorubicin hydrochloride in a pegylated liposomal formulation.

Caelyx, a liposome formulation, is doxorubicin hydrochloride encapsulated in liposomes with surface-bound methoxypolyethylene glycol (MPEG). This process is known as pegylation and protects liposomes from detection by the mononuclear phagocyte system (MPS), which increases blood circulation time.

For the full list of excipients, see section 6.1.

3.PHARMACEUTICAL FORM

Concentrate for solution for infusion

The suspension is sterile, translucent and red.

4.CLINICAL PARTICULARS

4.1Therapeutic indications

Caelyx is indicated:

-As monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk.

-For treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen.

-In combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant.

-For treatment of AIDS-related Kaposi’s sarcoma (KS) in patients with low CD4 counts

(< 200 CD4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease.

Caelyx may be used as first-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

4.2Posology and method of administration

Caelyx should only be administered under the supervision of a qualified oncologist specialised in the administration of cytotoxic agents.

Caelyx exhibits unique pharmacokinetic properties and must not be used interchangeably with other formulations of doxorubicin hydrochloride.

Posology

Breast cancer/Ovarian cancer

Caelyx is administered intravenously at a dose of 50 mg/m2 once every 4 weeks for as long as the disease does not progress and the patient continues to tolerate treatment.

Multiple myeloma

Caelyx is administered at 30 mg/m² on day 4 of the bortezomib 3 week regimen as a 1 hour infusion administered immediately after the bortezomib infusion. The bortezomib regimen consists of

1.3 mg/m² on days 1, 4, 8, and 11 every 3 weeks. The dose should be repeated as long as patients respond satisfactorily and tolerate treatment. Day 4 dosing of both medicinal products may be delayed up to 48 hours as medically necessary. Doses of bortezomib should be at least 72 hours apart.

AIDS-related KS

Caelyx is administered intravenously at 20 mg/m2 every two-to-three weeks. Avoid intervals shorter than 10 days as medicinal product accumulation and increased toxicity cannot be ruled out. Treatment of patients for two-to-three months is recommended to achieve a therapeutic response. Continue treatment as needed to maintain a therapeutic response.

For all patients

If the patient experiences early symptoms or signs of infusion reaction (see sections 4.4 and 4.8), immediately discontinue the infusion, give appropriate premedications (antihistamine and/or short acting corticosteroid) and restart at a slower rate.

Guidelines for Caelyx dose modification

To manage adverse events such as palmar-plantar erythrodysesthesia (PPE), stomatitis or haematological toxicity, the dose may be reduced or delayed. Guidelines for Caelyx dose modification secondary to these adverse effects are provided in the tables below. The toxicity grading in these tables is based on the National Cancer Institute Common Toxicity Criteria (NCI-CTC).

The tables for PPE (Table 1) and stomatitis (Table 2) provide the schedule followed for dose modification in clinical trials in the treatment of breast or ovarian cancer (modification of the recommended 4 week treatment cycle): if these toxicities occur in patients with AIDS-related KS, the recommended 2 to 3 week treatment cycle can be modified in a similar manner.

The table for haematological toxicity (Table 3) provides the schedule followed for dose modification in clinical trials in the treatment of patients with breast or ovarian cancer only. Dose modification in patients with AIDS-KS is addressed in section 4.8.

Table 1.

Palmar–Plantar erythrodysesthesia

 

 

 

 

 

Week after prior Caelyx dose

 

Toxicity grade at

Week 4

Week 5

 

Week 6

current assessment

 

 

 

 

Grade 1

Redose unless

Redose unless

 

Decrease dose by

(mild erythema,

patient has

patient has

 

25%; return to

swelling, or

experienced a previous

experienced a previous

 

4 week interval

desquamation not

grade 3 or 4 skin

grade 3 or 4 skin

 

 

interfering with daily

toxicity, in which case

toxicity, in which case

 

 

activities)

wait an additional

wait an additional

 

 

 

 

week

week

 

 

Grade 2

Wait an additional

Wait an additional

 

Decrease dose by

(erythema,

week

week

 

25%; return to

desquamation, or

 

 

 

4 week interval

swelling interfering

 

 

 

 

with, but not precluding

 

 

 

 

normal physical

 

 

 

 

activities; small blisters

 

 

 

 

or ulcerations less than

 

 

 

 

2 cm in diameter)

 

 

 

 

Grade 3

Wait an additional

Wait an additional

Withdraw patient

(blistering, ulceration,

week

week

 

or swelling interfering

 

 

 

 

with walking or normal

 

 

 

 

daily activities; cannot

 

 

 

 

wear regular clothing)

 

 

 

 

Grade 4

Wait an additional

Wait an additional

Withdraw patient

(diffuse or local process

week

week

 

causing infectious

 

 

 

 

complications, or a

 

 

 

 

bedridden state or

 

 

 

 

hospitalisation)

 

 

 

 

Table 2.

Stomatitis

 

 

 

 

 

 

 

Week after prior Caelyx dose

Toxicity grade at

 

Week 4

 

Week 5

Week 6

current assessment

 

 

 

 

 

Grade 1

 

Redose unless

 

Redose unless

Decrease dose by

(painless ulcers,

 

patient has

 

patient has

25%; return to

erythema, or mild

 

experienced a previous

 

experienced a previous

4 week interval or

soreness)

 

grade 3 or 4 stomatitis

 

grade 3 or 4 stomatitis

withdraw patient per

 

 

 

in which case wait an

 

in which case wait an

physician’s assessment

 

 

 

additional week

 

additional week

 

Grade 2

 

Wait an additional

 

Wait an additional

Decrease dose by

(painful erythema,

 

week

 

week

25%; return to

oedema, or ulcers, but

 

 

 

 

4 week interval or

can eat)

 

 

 

 

withdraw patient per

 

 

 

 

 

 

physician’s assessment

Grade 3

 

Wait an additional

 

Wait an additional

Withdraw patient

(painful erythema,

 

week

 

week

 

edema, or ulcers, but

 

 

 

 

 

cannot eat)

 

 

 

 

 

Grade 4

 

Wait an additional

 

Wait an additional

Withdraw patient

(requires parenteral or

 

week

 

week

 

enteral support)

 

 

 

 

 

Table 3.

Haematological toxicity (ANC or platelets) – Management of patients with breast

 

or ovarian cancer

 

 

GRADE

ANC

PLATELETS

MODIFICATION

Grade 1

1,500 – 1,900

75,000 – 150,000

Resume treatment with no dose

 

 

 

reduction.

Grade 2

1,000 – < 1,500

50,000 – < 75,000

Wait until ANC 1,500 and platelets

 

 

 

75,000; redose with no dose

 

 

 

reduction.

Grade 3

500 – < 1,000

25,000 – < 50,000

Wait until ANC 1,500 and platelets

 

 

 

75,000; redose with no dose

 

 

 

reduction.

Grade 4

< 500

< 25,000

Wait until ANC 1,500 and platelets

 

 

 

75,000; decrease dose by 25% or

 

 

 

continue full dose with growth factor

 

 

 

support.

For multiple myeloma patients treated with Caelyx in combination with bortezomib who experience PPE or stomatitis, the Caelyx dose should be modified as described in Table 1 and 2 above respectively. Table 4, below provides the schedule followed for other dose modifications in the clinical trial in the treatment of patients with multiple myeloma receiving Caelyx and bortezomib

combination therapy. For more detailed information on bortezomib dosing and dosage adjustments, see the SPC for bortezomib.

Table 4. Dosage adjustments for Caelyx + bortezomib combination therapy - patients with multiple myeloma

Patient status

Caelyx

Bortezomib

Fever ≥ 38C and ANC

Do not dose this cycle if before

Reduce next dose by 25%.

< 1,000/mm3

day 4; if after day 4, reduce

 

 

next dose by 25%.

 

On any day of medicine

Do not dose this cycle if before

Do not dose; if 2 or more doses

administration after day 1 of

day 4; if after day 4 reduce next

are not given in a cycle, reduce

each cycle:

dose by 25% in the following

dose by 25% in following

Platelet count < 25,000/mm3

cycles if bortezomib is reduced

cycles.

Hemoglobin < 8 g/dl

for hematologic toxicity.*

 

ANC < 500/mm3

 

 

Grade 3 or 4 non-hematologic

Do not dose until recovered to

Do not dose until recovered to

medicine related toxicity

grade < 2 and reduce dose by

grade < 2 and reduce dose by

 

25% for all subsequent doses.

25% for all subsequent doses.

Neuropathic pain or peripheral

No dosage adjustments.

See the SPC for bortezomib.

neuropathy

 

 

* for more information on bortezomib dosing and dosage adjustment, see the SPC for bortezomib

Hepatic Impairment

Caelyx pharmacokinetics determined in a small number of patients with elevated total bilirubin levels do not differ from patients with normal total bilirubin; however, until further experience is gained, the Caelyx dosage in patients with impaired hepatic function should be reduced based on the experience from the breast and ovarian clinical trial programs as follows: at initiation of therapy, if the bilirubin is between 1.2-3.0 mg/dl, the first dose is reduced by 25%. If the bilirubin is > 3.0 mg/dl, the first dose is reduced by 50%. If the patient tolerates the first dose without an increase in serum bilirubin or liver enzymes, the dose for cycle 2 can be increased to the next dose level, i.e., if reduced by 25% for the first dose, increase to full dose for cycle 2; if reduced by 50% for the first dose, increase to 75% of full dose for cycle 2. The dosage can be increased to full dose for subsequent cycles if tolerated. Caelyx can be administered to patients with liver metastases with concurrent elevation of bilirubin and liver enzymes up to 4 x the upper limit of the normal range. Prior to Caelyx administration, evaluate hepatic function using conventional clinical laboratory tests such as ALT/AST, alkaline phosphatase, and bilirubin.

Renal Impairment

As doxorubicin is metabolised by the liver and excreted in the bile, dose modification should not be required. Population pharmacokinetic data (in the range of creatinine clearance tested of

30-156 ml/min) demonstrate that Caelyx clearance is not influenced by renal function. No pharmacokinetic data are available in patients with creatinine clearance of less than 30 ml/min.

AIDS-related KS patients with splenectomy

As there is no experience with Caelyx in patients who have had splenectomy, treatment with Caelyx is not recommended.

Paediatric population

The experience in children is limited. Caelyx is not recommended in patients below 18 years of age.

Elderly

Population based analysis demonstrates that age across the range tested (21–75 years) does not significantly alter the pharmacokinetics of Caelyx.

Method of administration

Caelyx is administered as an intravenous infusion. For further instructions on preparation and special precautions for handling see section 6.6.

Do not administer Caelyx as a bolus injection or undiluted solution. It is recommended that the Caelyx infusion line be connected through the side port of an intravenous infusion of 5% (50 mg/ml) glucose to achieve further dilution and minimise the risk of thrombosis and extravasation. The infusion may be given through a peripheral vein. Do not use with in-line filters. Caelyx must not be given by the intramuscular or subcutaneous route (see section 6.6).

For doses < 90 mg: dilute Caelyx in 250 ml 5% (50 mg/ml) glucose solution for infusion. For doses 90 mg: dilute Caelyx in 500 ml 5% (50 mg/ml) glucose solution for infusion.

Breast cancer/Ovarian cancer/Multiple myeloma

To minimise the risk of infusion reactions, the initial dose is administered at a rate no greater than 1 mg/minute. If no infusion reaction is observed, subsequent Caelyx infusions may be administered over a 60-minute period.

In those patients who experience an infusion reaction, the method of infusion should be modified as follows:

5% of the total dose should be infused slowly over the first 15 minutes. If tolerated without reaction, the infusion rate may then be doubled for the next 15 minutes. If tolerated, the infusion may then be completed over the next hour for a total infusion time of 90 minutes.

AIDS-related KS

The dose of Caelyx is diluted in 250 ml 5% (50 mg/ml) glucose solution for infusion and administered by intravenous infusion over 30 minutes.

4.3Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Caelyx must not be used to treat AIDS-KS that may be treated effectively with local therapy or systemic alfa-interferon.

4.4Special warnings and precautions for use

Given the difference in pharmacokinetic profiles and dosing schedules, Caelyx should not be used interchangeably with other formulations of doxorubicin hydrochloride.

Cardiac toxicity

It is recommended that all patients receiving Caelyx routinely undergo frequent ECG monitoring. Transient ECG changes such as T-wave flattening, S-T segment depression and benign arrhythmias are not considered mandatory indications for the suspension of Caelyx therapy. However, reduction of the QRS complex is considered more indicative of cardiac toxicity. If this change occurs, the most definitive test for anthracycline myocardial injury, i.e., endomyocardial biopsy, must be considered.

More specific methods for the evaluation and monitoring of cardiac functions as compared to ECG are a measurement of left ventricular ejection fraction by echocardiography or preferably by Multigated Angiography (MUGA). These methods must be applied routinely before the initiation of Caelyx therapy and repeated periodically during treatment. The evaluation of left ventricular function is considered to be mandatory before each additional administration of Caelyx that exceeds a lifetime cumulative anthracycline dose of 450 mg/m2.

The evaluation tests and methods mentioned above concerning the monitoring of cardiac performance during anthracycline therapy are to be employed in the following order: ECG monitoring, measurement of left ventricular ejection fraction, endomyocardial biopsy. If a test result indicates possible cardiac injury associated with Caelyx therapy, the benefit of continued therapy must be carefully weighed against the risk of myocardial injury.

In patients with cardiac disease requiring treatment, administer Caelyx only when the benefit outweighs the risk to the patient.

Exercise caution in patients with impaired cardiac function who receive Caelyx.

Whenever cardiomyopathy is suspected, i.e., the left ventricular ejection fraction has substantially decreased relative to pre-treatment values and/or left ventricular ejection fraction is lower than a prognostically relevant value (e.g., < 45%), endomyocardial biopsy may be considered and the benefit of continued therapy must be carefully evaluated against the risk of developing irreversible cardiac damage.

Congestive heart failure due to cardiomyopathy may occur suddenly, without prior ECG changes and may also be encountered several weeks after discontinuation of therapy.

Caution must be observed in patients who have received other anthracyclines. The total dose of doxorubicin hydrochloride must also take into account any previous (or concomitant) therapy with cardiotoxic compounds such as other anthracyclines/anthraquinones or e.g., 5-fluorouracil. Cardiac toxicity also may occur at cumulative anthracycline doses lower than 450 mg/m2 in patients with prior mediastinal irradiation or in those receiving concurrent cyclophosphamide therapy.

The cardiac safety profile for the dosing schedule recommended for both breast and ovarian cancer (50 mg/m2) is similar to the 20 mg/m2 profile in patients with AIDS-KS (see section 4.8).

Myelosuppression

Many patients treated with Caelyx have baseline myelosuppression due to such factors as their pre-existing HIV disease or numerous concomitant or previous medications, or tumours involving bone marrow. In the pivotal trial in patients with ovarian cancer treated at a dose of 50 mg/m2, myelosuppression was generally mild to moderate, reversible, and was not associated with episodes of neutropaenic infection or sepsis. Moreover, in a controlled clinical trial of Caelyx vs. topotecan, the incidence of treatment related sepsis was substantially less in the Caelyx-treated ovarian cancer patients as compared to the topotecan treatment group. A similar low incidence of myelosuppression was seen in patients with metastatic breast cancer receiving Caelyx in a first-line clinical trial. In contrast to the experience in patients with breast cancer or ovarian cancer, myelosuppression appears to be the dose-limiting adverse event in patients with AIDS-KS (see section 4.8). Because of the potential for bone marrow suppression, periodic blood counts must be performed frequently during the course of Caelyx therapy, and at a minimum, prior to each dose of Caelyx.

Persistent severe myelosuppression, may result in superinfection or haemorrhage.

In controlled clinical studies in patients with AIDS-KS against a bleomycin/vincristine regimen, opportunistic infections were apparently more frequent during treatment with Caelyx. Patients and doctors must be aware of this higher incidence and take action as appropriate.

Secondary haematological malignancies

As with other DNA-damaging antineoplastic agents, secondary acute myeloid leukemias and myelodysplasias have been reported in patients having received combined treatment with doxorubicin. Therefore, any patient treated with doxorubicin should be kept under haematological supervision.

Secondary oral neoplasms

Very rare cases of secondary oral cancer have been reported in patients with long-term (more than one year) exposure to Caelyx or those receiving a cumulative Caelyx dose greater than 720 mg/m2. Cases of secondary oral cancer were diagnosed both, during treatment with Caelyx, and up to 6 years after the last dose. Patients should be examined at regular intervals for the presence of oral ulceration or any oral discomfort that may be indicative of secondary oral cancer.

Infusion-associated reactions

Serious and sometimes life-threatening infusion reactions, which are characterised by allergic-like or anaphylactoid-like reactions, with symptoms including asthma, flushing, urticarial rash, chest pain, fever, hypertension, tachycardia, pruritus, sweating, shortness of breath, facial oedema, chills, back pain, tightness in the chest and throat and/or hypotension may occur within minutes of starting the infusion of Caelyx. Very rarely, convulsions also have been observed in relation to infusion reactions (see section 4.8). Temporarily stopping the infusion usually resolves these symptoms without further therapy. However, medications to treat these symptoms (e.g., antihistamines, corticosteroids, adrenaline, and anticonvulsants), as well as emergency equipment should be available for immediate use. In most patients treatment can be resumed after all symptoms have resolved, without recurrence. Infusion reactions rarely recur after the first treatment cycle. To minimise the risk of infusion reactions, the initial dose should be administered at a rate no greater than 1 mg/minute (see section 4.2).

Diabetic patients

Please note that each vial of Caelyx contains sucrose and the dose is administered in 5% (50 mg/ml) glucose solution for infusion.

For common adverse events which required dose modification or discontinuation see section 4.8.

4.5Interaction with other medicinal products and other forms of interaction

No formal medicinal product interaction studies have been performed with Caelyx, although phase II combination trials with conventional chemotherapy agents have been conducted in patients with gynaecological malignancies. Exercise caution in the concomitant use of medicinal products known to interact with standard doxorubicin hydrochloride. Caelyx, like other doxorubicin hydrochloride preparations, may potentiate the toxicity of other anti-cancer therapies. During clinical trials in patients with solid tumours (including breast and ovarian cancer) who have received concomitant cyclophosphamide or taxanes, no new additive toxicities were noted. In patients with AIDS, exacerbation of cyclophosphamide-induced haemorrhagic cystitis and enhancement of the hepatotoxicity of 6-mercaptopurine have been reported with standard doxorubicin hydrochloride. Caution must be exercised when giving any other cytotoxic agents, especially myelotoxic agents, at the same time.

4.6Fertility, pregnancy and lactation

Pregnancy

Doxorubicin hydrochloride is suspected to cause serious birth defects when administered during pregnancy. Therefore, Caelyx should not be used during pregnancy unless clearly necessary.

Women of child-bearing potential

Women of child-bearing potential must be advised to avoid pregnancy while they or their male partner are receiving Caelyx and in the six months following discontinuation of Caelyx therapy (see section 5.3).

Breast-feeding

It is not known whether Caelyx is excreted in human milk. Because many medicinal products, including anthracyclines, are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants, therefore mothers must discontinue nursing prior to beginning Caelyx treatment. Health experts recommend that HIV infected women do not breast-feed their infants under any circumstances in order to avoid transmission of HIV.

Fertility

The effect of doxorubicin hydrochloride on human fertility has not been evaluated (see section 5.3).

4.7Effects on ability to drive and use machines

Caelyx has no or negligible influence on the ability to drive and use machines. However, in clinical studies to date, dizziness and somnolence were associated infrequently (< 5%) with the administration of Caelyx. Patients who suffer from these effects must avoid driving and operating machinery.

4.8Undesirable effects

Summary of the safety profile

The most common undesirable effect reported in breast/ovarian clinical trials (50 mg/m2 every

4 weeks) was palmar-plantar erythrodysesthesia (PPE). The overall incidence of PPE reported was 44.0%-46.1%. These effects were mostly mild, with severe (grade 3) cases reported in 17%-19.5%. The reported incidence of life-threatening (grade 4) cases was < 1%. PPE infrequently resulted in permanent treatment discontinuation (3.7%-7.0%). PPE is characterised by painful, macular reddening skin eruptions. In patients experiencing this event, it is generally seen after two or three cycles of treatment. Improvement usually occurs in one - two weeks, and in some cases, may take up to 4 weeks or longer for complete resolution. Pyridoxine at a dose of 50-150 mg per day and corticosteroids have been used for the prophylaxis and treatment of PPE, however, these therapies have not been evaluated in phase III trials. Other strategies to prevent and treat PPE include keeping hands and feet cool, by exposing them to cool water (soaks, baths, or swimming), avoiding excessive heat/hot water and keeping them unrestricted (no socks, gloves, or shoes that are tight fitting). PPE appears to be primarily related to the dose schedule and can be reduced by extending the dose interval 1-2 weeks (see section 4.2). However, this reaction can be severe and debilitating in some patients and may require discontinuation of treatment. Stomatitis/mucositis and nausea were also commonly reported in breast/ovarian cancer patient populations, whereas the AIDS-KS Program (20 mg/m2 every 2 weeks), myelosuppression (mostly leukopaenia) was the most common side effect (see AIDS-KS). PPE was reported in 16% of multiple myeloma patients treated with Caelyx plus bortezomib combination therapy. Grade 3 PPE was reported in 5% of patients. No grade 4 PPE was reported. The most frequently reported (medicine-related treatment-emergent) adverse events in combination therapy (Caelyx + bortezomib) were nausea (40%), diarrhoea (35%), neutropaenia (33%), thrombocytopaenia (29%), vomiting (28%), fatigue (27%), and constipation (22%).

Breast cancer program

509 patients with advanced breast cancer who had not received prior chemotherapy for metastatic disease were treated with Caelyx (n=254) at a dose of 50 mg/m2 every 4 weeks, or doxorubicin (n=255) at a dose of 60 mg/m2 every 3 weeks, in a phase III clinical trial (I97-328). The following common adverse events were reported more often with doxorubicin than with Caelyx: nausea (53% vs. 37%; grade 3/4 5% vs. 3%), vomiting (31% vs. 19%; grade 3/4 4% vs. less than 1%), any alopecia (66% vs. 20%), pronounced alopecia (54% vs.7%), and neutropaenia (10% vs. 4%; grade 3/4 8% vs. 2%).

Mucositis (23% vs. 13%; grade 3/4 4% vs. 2%), and stomatitis (22% vs. 15%; grade 3/4 5% vs. 2%) were reported more commonly with Caelyx than with doxorubicin. The average duration of the most common severe (grade 3/4) events for both groups was 30 days or less. See Table 5 for complete listing of undesirable effects reported in Caelyx-treated patients.

The incidence of life threatening (grade 4) haematologic effects was < 1.0% and sepsis was reported in 1% of patients. Growth factor support or transfusion support was necessary in 5.1% and 5.5% of patients, respectively (see section 4.2).

Clinically significant laboratory abnormalities (grades 3 and 4) in this group was low with elevated total bilirubin, AST and ALT reported in 2.4%, 1.6% and < 1% of patients respectively. No clinically significant increases in serum creatinine were reported.

Table 5. Treatment related undesirable effects reported in breast cancer clinical trials (50 mg/m2 every 4 weeks) (Caelyx-treated patients) by severity, MedDRA system organ class and preferred term

Very common (≥ 1/10); Common (≥ 1/100, < 1/10); Uncommon (≥ 1/1,000, < 1/100)

CIOMS III

AE by body system

Breast cancer

 

Breast cancer

Breast cancer

 

All severities

 

n=404

 

n=254

 

n=254

(1-5%)

 

( 5%)

 

( 5%)

not previously

 

 

 

 

reported in clinical

 

 

 

 

trials

Infections and infestations

 

 

Common

Pharyngitis

 

 

Folliculitis, fungal

 

 

 

 

infection, cold sores

 

 

 

 

(non-herpetic), upper

 

 

 

 

respiratory tract

 

 

 

 

infection

Uncommon

 

 

Pharyngitis

 

Blood and lymphatic system disorders

 

 

Common

Leukopaenia, anaemia,

 

Leukopaenia, anaemia

Thrombocythemia

 

neutropaenia,

 

 

 

 

thrombocytopaenia

 

 

 

Uncommon

 

 

Neutropaenia

 

Metabolism and nutrition disorders

 

 

Very common

Anorexia

 

 

 

Common

 

 

Anorexia

 

Nervous system disorders

 

 

Common

Paresthesia

 

Paresthesia

Peripheral neuropathy

Uncommon

Somnolence

 

 

 

Eye disorders

 

 

 

 

Common

 

 

 

Lacrimation, blurred

 

 

 

 

vision

Cardiac disorders

 

 

 

 

Common

 

 

 

Ventricular arrhythmia

Respiratory, thoracic and mediastinal disorders

 

 

Common

 

 

 

Epistaxis

Gastrointestinal disorders

 

 

Very common

Nausea, stomatitis,

 

 

 

 

vomiting

 

 

 

Common

Abdominal pain,

 

Abdominal pain,

Oral pain

 

constipation,

 

diarrhoea, nausea,

 

 

diarrhoea, dyspepsia,

 

stomatitis

 

 

mouth ulceration

 

 

 

Uncommon

 

 

Mouth ulceration,

 

 

 

 

constipation, vomiting

 

Skin and subcutaneous tissue disorders

 

 

Very common

PPE*, alopecia, rash

 

PPE*

 

 

 

 

 

 

Common

Dry skin, skin

 

Rash

Bullous eruption,

 

discolouration,

 

 

dermatitis,

 

pigmentation

 

 

erythematous rash, nail

 

abnormal, erythema

 

 

disorder, scaly skin

Uncommon

 

 

Pigmentation

 

 

 

 

abnormal, erythema

 

Musculoskeletal and connective tissue disorders

 

 

Common

 

 

 

Leg cramps, bone

 

 

 

 

pain, musculoskeletal

 

 

 

 

pain

Reproductive system and breast disorders

 

 

Common

 

 

 

Breast pain

General disorders and administration site conditions

 

Very common

Asthenia, fatigue,

 

 

 

 

mucositis NOS

 

 

 

Common

Weakness, fever, pain

 

Asthenia, mucositis

Oedema, leg oedema.

 

 

 

NOS

 

Uncommon

 

 

Fatigue, weakness,

 

 

 

 

pain

 

* palmar-plantar erythrodysesthesia (Hand-foot syndrome).

 

 

Ovarian cancer program

512 patients with ovarian cancer (a subset of 876 solid tumour patients) were treated with Caelyx at a dose of 50 mg/m2 in clinical trials. See Table 6 for undesirable effects reported in Caelyx-treated patients.

Table 6. Treatment related undesirable effects reported in ovarian cancer clinical trials (50 mg/m2 every 4 weeks) (Caelyx-treated patients) by severity, MedDRA system organ class and preferred term

Very common (≥ 1/10); Common (≥ 1/100, < 1/10); Uncommon (≥ 1/1,000, < 1/100)

CIOMS III

AE by body system

Ovarian cancer

Ovarian cancer

Ovarian cancer

 

All severities

n=512

 

n=512

n=512

(1-5%)

 

( 5%)

( 5%)

 

Infections and infestations

 

 

Common

Pharyngitis

 

Infection, oral

 

 

 

moniliasis, herpes

 

 

 

zoster, urinary tract

 

 

 

infection

Uncommon

 

Pharyngitis

 

Blood and lymphatic system disorders

 

 

Very common

Leukopaenia, anaemia,

Neutropaenia

 

 

neutropaenia,

 

 

 

thrombocytopaenia

 

 

Common

 

Leukopaenia, anaemia,

Hypochromic anaemia

 

 

thrombocytopaenia

 

Immune system disorders

 

 

Common

 

 

Allergic reaction

Metabolism and nutrition disorders

Very common

Anorexia

 

 

 

Common

 

 

 

Dehydration, cachexia

Uncommon

 

 

Anorexia

 

Psychiatric disorders

 

 

 

 

Common

 

 

 

Anxiety, depression,

 

 

 

 

insomnia

Nervous system disorders

 

 

Common

Paresthesia,

 

 

Headache, dizziness,

 

somnolence

 

 

neuropathy, hypertonia

Uncommon

 

 

Paresthesia,

 

 

 

 

somnolence

 

Eye disorders

 

 

 

 

Common

 

 

 

Conjunctivitis

Cardiac disorders

 

 

 

 

Common

 

 

 

Cardiovascular

 

 

 

 

disorder

Vascular disorders

 

 

 

 

Common

 

 

 

Vasodilatation

Respiratory, thoracic and mediastinal disorders

 

 

Common

 

 

 

Dyspnoea, increased

 

 

 

 

cough

Gastrointestinal disorders

 

 

Very common

Constipation,

 

 

 

 

diarrhoea, nausea,

 

 

 

 

stomatitis, vomiting

 

 

 

Common

Abdominal pain,

 

Nausea, stomatitis,

Mouth ulceration,

 

dyspepsia, mouth

 

vomiting, abdominal

esophagitis, nausea

 

ulceration

 

pain, diarrhoea

and vomiting, gastritis,

 

 

 

 

dysphagia, dry mouth,

 

 

 

 

flatulence, gingivitis,

 

 

 

 

taste perversion

Uncommon

 

 

Constipation,

 

 

 

 

dyspepsia, mouth

 

 

 

 

ulceration

 

Skin and subcutaneous tissue disorders

 

 

Very common

PPE*, alopecia, rash

 

PPE*

 

Common

Dry skin, skin

 

Alopecia, rash

Vesiculobullous rash,

 

discolouration

 

 

pruritus, exfoliative

 

 

 

 

dermatitis, skin

 

 

 

 

disorder,

 

 

 

 

maculopapular rash,

 

 

 

 

sweating, acne, skin

 

 

 

 

ulcer

Musculoskeletal and connective tissue disorders

 

 

Common

 

 

 

Back pain, myalgia

Renal and urinary disorders

 

 

Common

 

 

 

Dysuria

Reproductive system and breast disorders

 

 

Common

 

 

 

Vaginitis

General disorders and administration site conditions

Very common

Asthenia, mucous

 

 

 

membrane disorder

 

 

Common

Fever, pain

Asthenia, mucous

Chills, chest pain,

 

 

membrane disorder,

malaise, peripheral

 

 

pain

oedema

Uncommon

 

Fever

 

Investigations

 

 

 

Common

 

 

Weight loss

* palmar-plantar erythrodysesthesia (Hand-foot syndrome).

Myelosuppression was mostly mild or moderate and manageable. Sepsis related to leukopaenia was observed infrequently (< 1%). Growth factor support was required infrequently (< 5%) and transfusion support was required in approximately 15% of patients (see section 4.2).

In a subset of 410 patients with ovarian cancer, clinically significant laboratory abnormalities occurring in clinical trials with Caelyx included increases in total bilirubin (usually in patients with liver metastases) (5%) and serum creatinine levels (5%). Increases in AST were less frequently (< 1%) reported.

Solid tumour patients: in a larger cohort of 929 patients with solid tumours (including breast cancer and ovarian cancer) predominantly treated at a dose of 50 mg/m2 every 4 weeks, the safety profile and incidence of adverse effects are comparable to those of the patients treated in the pivotal breast cancer and ovarian cancer trials.

Multiple myeloma program

Of 646 patients with multiple myeloma who have received at least 1 prior therapy, 318 patients were treated with combination therapy of Caelyx 30 mg/m2 as a one hour intravenous infusion administered on day 4 following bortezomib which is administered at 1.3 mg/m² on days 1, 4, 8, and 11, every three weeks or with bortezomib monotherapy in a phase III clinical trial. See Table 7 for adverse effects reported in ≥ 5% patients treated with combination therapy of Caelyx plus bortezomib.

Neutropaenia, thrombocytopaenia, and anaemia were the most frequently reported hematologic events reported with both combination therapy of Caelyx plus bortezomib and bortezomib monotherapy. The incidence of grade 3 and 4 neutropaenia was higher in the combination therapy group than in the monotherapy group (28% vs. 14%). The incidence of grade 3 and 4 thrombocytopaenia was higher in the combination therapy group than in the monotherapy group (22% vs. 14%). The incidence of anaemia was similar in both treatment groups (7% vs. 5%).

Stomatitis was reported more frequently in the combination therapy group (16%) than in the monotherapy group (3%), and most cases were grade 2 or less in severity. Grade 3 stomatitis was reported in 2% of patients in the combination therapy group. No grade 4 stomatitis was reported.

Nausea and vomiting were reported more frequently in the combination therapy group (40% and 28%) than in the monotherapy group (32% and 15%) and were mostly grade 1 and 2 in severity.

Treatment discontinuation of one or both agents due to adverse events was seen in 38% of patients. Common adverse events which led to treatment discontinuation of bortezomib and Caelyx included PPE, neuralgia, peripheral neuropathy, peripheral sensory neuropathy, thrombocytopaenia, decreased ejection fraction, and fatigue.

Table 7. Treatment related undesirable effects reported in multiple myeloma clinical trial (Caelyx 30 mg/m2 in combination with bortezomib every 3 weeks) by severity, MedDRA system organ class and preferred term

Very common (≥ 1/10); Common (≥ 1/100, < 1/10); Uncommon (≥ 1/1,000, < 1/100)

CIOMS III

AE by body system

All Severities

Grades 3/4**

All Severities

 

n=318

n=318

n=318

 

( 5%)

( 5%)

(1-5%)

Infections and infestations

 

 

Common

Herpes simplex,

Herpes zoster

Pneumonia,

 

herpes zoster

 

nasopharyngitis, upper

 

 

 

respiratory tract

 

 

 

infection, oral

 

 

 

candidiasis

Blood and lymphatic system disorders

 

 

Very common

Anaemia,

Neutropaenia,

 

 

neutropaenia,

thrombocytopaenia

 

 

thrombocytopaenia

 

 

Common

Leukopaenia

Anaemia, leukopaenia

Febrile neutropaenia,

 

 

 

lymphopaenia

Metabolism and nutrition disorders

 

 

Very common

Anorexia

 

 

Common

Decreased appetite

Anorexia

Dehydration,

 

 

 

hypokalaemia,

 

 

 

hyperkalaemia,

 

 

 

hypomagnesaemia,

 

 

 

hyponatraemia,

 

 

 

hypocalcaemia

Uncommon

 

Decreased appetite

 

Psychiatric disorders

 

 

 

Common

Insomnia

 

Anxiety

Nervous system disorders

 

 

Very common

Peripheral sensory

 

 

 

neuropathy, neuralgia,

 

 

 

headache

 

 

Common

Neuropathy peripheral,

Neuralgia, peripheral

Lethargy,

 

neuropathy,

neuropathy,

hypoaesthesia,

 

paraesthesia,

neuropathy

syncope, dysaesthesia

 

polyneuropathy,

 

 

 

dizziness, dysgeusia

 

 

Uncommon

 

Headache, peripheral

 

 

 

sensory neuropathy,

 

 

 

paraesthesia, dizziness

 

Eye disorders

 

 

 

Common

 

 

Conjunctivitis

Vascular disorders

 

 

 

Common

 

 

Hypotension,

 

 

 

orthostatic

 

 

 

hypotension, flushing,

 

 

 

hypertension, phlebitis

Respiratory, thoracic and mediastinal disorders

Common

Dyspnoea

 

 

Cough, epistaxis

 

 

 

 

exertional dyspnoea

Uncommon

 

 

Dyspnoea

 

Gastrointestinal disorders

 

 

Very common

Nausea, diarrhoea,

 

 

 

 

vomiting, constipation,

 

 

 

 

stomatitis

 

 

 

Common

Abdominal pain,

 

Nausea, diarrhoea,

Upper abdominal pain,

 

dyspepsia

 

vomiting, stomatitis

mouth ulceration, dry

 

 

 

 

mouth, dysphagia,

 

 

 

 

aphthous stomatitis

Uncommon

 

 

Constipation,

 

 

 

 

abdominal pain,

 

 

 

 

dyspepsia

 

Skin and subcutaneous tissue disorders

 

 

Very common

PPE*, rash

 

 

 

Common

Dry skin

 

PPE*

Pruritus, papular rash,

 

 

 

 

allergic dermatitis,

 

 

 

 

erythema, skin

 

 

 

 

hyperpigmentation,

 

 

 

 

petechiae, alopecia,

 

 

 

 

medicine eruption

Uncommon

 

 

Rash

 

Musculoskeletal and connective tissue disorders

 

 

Common

Pain in extremity

 

 

Arthralgia, myalgia,

 

 

 

 

muscle spasms,

 

 

 

 

muscular weakness,

 

 

 

 

musculoskeletal pain,

 

 

 

 

musculoskeletal chest

 

 

 

 

pain

Reproductive system and breast disorders

 

 

Common

 

 

 

Scrotal erythema

General disorders and administration site conditions

 

Very common

Asthenia, fatigue,

 

 

 

 

pyrexia

 

 

 

Common

 

 

Asthenia, fatigue

Peripheral oedema,

 

 

 

 

chills, influenza-like

 

 

 

 

illness, malaise,

 

 

 

 

hyperthermia

Uncommon

 

 

Pyrexia

 

Investigations

 

 

 

 

Common

Weight decreased

 

 

Aspartate

 

 

 

 

aminotransferase

 

 

 

 

increased, ejection

 

 

 

 

fraction decreased,

 

 

 

 

blood creatinine

 

 

 

 

increased, alanine

 

 

 

 

aminotransferase

 

 

 

 

increased

*Palmar-plantar erythrodysesthesia (Hand-foot syndrome).

**Grade 3/4 adverse events are based on the adverse event terms of all severities with an overall incidence ≥ 5% (see adverse events listed in first column).

AIDS-related KS program

Clinical studies on AIDS-KS patients treated at 20 mg/m2 with Caelyx show that myelosuppression was the most frequent undesirable effect considered related to Caelyx occurring very commonly (in approximately one-half of the patients).

Leukopaenia is the most frequent undesirable effect experienced with Caelyx in this population; neutropaenia, anaemia and thrombocytopaenia have been observed. These effects may occur early on in treatment. Haematological toxicity may require dose reduction or suspension or delay of therapy. Temporarily suspend Caelyx treatment in patients when the ANC count is < 1,000/mm3 and/or the platelet count is < 50,000/mm3. G-CSF (or GM-CSF) may be given as concomitant therapy to support the blood count when the ANC count is < 1,000/mm3 in subsequent cycles. The haematological toxicity for ovarian cancer patients is less severe than in the AIDS-KS setting (see section for ovarian cancer patients above).

Respiratory undesirable effects commonly occurred in clinical studies of Caelyx and may be related to opportunistic infections in the AIDS population. Opportunistic infections (OI’s) are observed in KS patients after administration with Caelyx, and are frequently observed in patients with HIV-induced immunodeficiency. The most frequently observed OI’s in clinical studies were candidiasis, cytomegalovirus, herpes simplex, Pneumocystis carinii pneumonia, and mycobacterium avium complex.

Table 8. Undesirable effects observed in patients with AIDS-related KS according to CIOMS III frequency categories

Very common (≥ 1/10); Common (≥ 1/100, < 1/10); Uncommon (≥ 1/1,000, < 1/100)

Infections and infestations

common

 

oral moniliasis

Blood and lymphatic system disorders

 

very common

 

neutropaenia, anaemia, leukopaenia

common

 

thrombocytopaenia

Metabolism and nutrition disorders

 

common

 

anorexia

Psychiatric disorders

 

uncommon

 

confusion

Nervous system disorders

 

common

 

dizziness

uncommon

 

paresthesia

Eye disorders

 

common

 

retinitis

Vascular disorders

 

common

 

vasodilatation

Respiratory, thoracic and mediastinal disorders

 

common

 

dyspnoea

Gastrointestinal disorders

 

very common

 

nausea

common

 

diarrhoea, stomatitis, vomiting, mouth

 

 

ulceration, abdominal pain, glossitis,

 

 

constipation, nausea and vomiting

Skin and subcutaneous tissue disorders

common

alopecia, rash

uncommon

palmar-plantar erythrodysesthesia (PPE)

General disorders and administration site conditions

common

asthenia, fever, infusion-associated acute

 

reactions

Investigations

 

common

weight loss

Other less frequently (< 5%) observed undesirable effects included hypersensitivity reactions including anaphylactic reactions. Following marketing, bullous eruption has been reported rarely in this population.

Clinically significant laboratory abnormalities frequently ( 5%) occurred including increases in alkaline phosphatase; AST and bilirubin which were believed to be related to the underlying disease and not Caelyx. Reduction in haemoglobin and platelets were less frequently (< 5%) reported. Sepsis related to leukopaenia was rarely (< 1%) observed. Some of these abnormalities may have been related to the underlying HIV infection and not Caelyx.

All patients

100 out of 929 patients (10.8%) with solid tumours were described as having an infusion-associated reaction during treatment with Caelyx as defined by the following Costart terms: allergic reaction, anaphylactoid reaction, asthma, face oedema, hypotension, vasodilatation, urticaria, back pain, chest pain, chills, fever, hypertension, tachycardia, dyspepsia, nausea, dizziness, dyspnoea, pharyngitis, rash, pruritus, sweating, injection site reaction and medicinal product interaction. Permanent treatment discontinuation was infrequently reported at 2%. A similar incidence of infusion reactions (12.4%) and treatment discontinuation (1.5%) was observed in the breast cancer program. In patients with multiple myeloma receiving Caelyx plus bortezomib, infusion-associated reactions have been reported at a rate of 3%. In patients with AIDS-KS, infusion-associated reactions, were characterised by flushing, shortness of breath, facial oedema, headache, chills, back pain, tightness in the chest and throat and/or hypotension and can be expected at the rate of 5% to 10%. Very rarely, convulsions have been observed in relation to infusion reactions. In all patients, infusion-associated reactions occurred primarily during the first infusion. Temporarily stopping the infusion usually resolves these symptoms without further therapy. In nearly all patients, Caelyx treatment can be resumed after all symptoms have resolved without recurrence. Infusion reactions rarely recur after the first treatment cycle with Caelyx (see section 4.2).

Myelosuppression associated with anaemia, thrombocytopaenia, leukopaenia, and rarely febrile neutropaenia, has been reported in Caelyx-treated patients.

Stomatitis has been reported in patients receiving continuous infusions of conventional doxorubicin hydrochloride and was frequently reported in patients receiving Caelyx. It did not interfere with patients completing therapy and no dosage adjustments are generally required, unless stomatitis is affecting a patient’s ability to eat. In this case, the dose interval may be extended by 1-2 weeks or the dose reduced (see section 4.2).

An increased incidence of congestive heart failure is associated with doxorubicin therapy at cumulative lifetime doses > 450 mg/m2 or at lower doses for patients with cardiac risk factors. Endomyocardial biopsies on nine of ten AIDS-KS patients receiving cumulative doses of Caelyx greater than 460 mg/m2 indicate no evidence of anthracycline-induced cardiomyopathy. The recommended dose of Caelyx for AIDS-KS patients is 20 mg/m2 every two-to-three weeks. The cumulative dose at which cardiotoxicity would become a concern for these AIDS-KS patients (> 400 mg/m2) would require more than 20 courses of Caelyx therapy over 40 to 60 weeks.

In addition, endomyocardial biopsies were performed in 8 solid tumour patients with cumulative anthracycline doses of 509 mg/m2–1,680 mg/m2. The range of Billingham cardiotoxicity scores was grades 0-1.5. These grading scores are consistent with no or mild cardiac toxicity.

In the pivotal phase III trial versus doxorubicin, 58/509 (11.4%) randomised subjects (10 treated with Caelyx at a dose of 50 mg/m2/every 4 weeks versus 48 treated with doxorubicin at a dose of

60 mg/m2/every 3 weeks) met the protocol-defined criteria for cardiac toxicity during treatment and/or follow-up. Cardiac toxicity was defined as a decrease of 20 points or greater from baseline if the resting LVEF remained in the normal range or a decrease of 10 points or greater if the LVEF became abnormal (less than the lower limit for normal). None of the 10 Caelyx subjects who had cardiac toxicity by LVEF criteria developed signs and symptoms of CHF. In contrast, 10 of 48 doxorubicin subjects who had cardiac toxicity by LVEF criteria also developed signs and symptoms of CHF.

In patients with solid tumours, including a subset of patients with breast and ovarian cancers, treated at a dose of 50 mg/m2/cycle with lifetime cumulative anthracycline doses up to 1,532 mg/m2, the incidence of clinically significant cardiac dysfunction was low. Of the 418 patients treated with Caelyx 50 mg/m2/cycle, and having a baseline measurement of left ventricular ejection fraction (LVEF) and at least one follow-up measurement assessed by MUGA scan, 88 patients had a cumulative anthracycline dose of > 400 mg/m2, an exposure level associated with an increased risk of cardiovascular toxicity with conventional doxorubicin. Only 13 of these 88 patients (15%) had at least one clinically significant change in their LVEF, defined as an LVEF value less than 45% or a decrease of at least 20 points from baseline. Furthermore, only 1 patient (cumulative anthracycline dose of

944 mg/m2), discontinued study treatment because of clinical symptoms of congestive heart failure.

As with other DNA-damaging antineoplastic agents, secondary acute myeloid leukemias and myelodysplasias have been reported in patients having received combined treatment with doxorubicin. Therefore, any patient treated with doxorubicin should be kept under haematological supervision.

Although local necrosis following extravasation has been reported very rarely, Caelyx is considered to be an irritant. Animal studies indicate that administration of doxorubicin hydrochloride as a liposomal formulation reduces the potential for extravasation injury. If any signs or symptoms of extravasation occur (e.g., stinging, erythema) terminate the infusion immediately and restart in another vein. The application of ice over the site of extravasation for approximately 30 minutes may be helpful in alleviating the local reaction. Caelyx must not be given by the intramuscular or subcutaneous route.

Recall of skin reaction due to prior radiotherapy has rarely occurred with Caelyx administration.

Post-marketing experience

Adverse drug reactions identified during the post-marketing experience with Caelyx are described in Table 9. The frequencies are provided according to the following convention:

Very common

1/10

Common

1/100 and < 1/10

Uncommon

1/1,000 and < 1/100

Rare

1/10,000, < 1/1,000

Very rare

< 1/10,000 including isolated reports

Table 9. Adverse drug reactions identified during the post-marketing experience with Caelyx

Neoplasms benign, malignant and unspecified (incl cysts and polyps)

very rare

secondary oral neoplasms1

Vascular disorders

 

uncommon

venous thromboembolism, including

 

thrombophlebitis, venous thrombosis and

 

pulmonary embolism

Skin and subcutaneous tissue disorders

very rareerythema multiforme, Stevens Johnson syndrome and toxic epidermal necrolysis

1Cases of secondary oral cancer have been reported in patients with long-term (more than one year) exposure to Caelyx or those receiving a cumulative Caelyx dose greater than 720 mg/m2 (see section 4.4).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

4.9Overdose

Acute overdosing with doxorubicin hydrochloride worsens the toxic effects of mucositis, leukopaenia and thrombocytopaenia. Treatment of acute overdose of the severely myelosuppressed patient consists of hospitalisation, antibiotics, platelet and granulocyte transfusions and symptomatic treatment of mucositis.

5.PHARMACOLOGICAL PROPERTIES

5.1Pharmacodynamic properties

Pharmacotherapeutic group: Cytotoxic agents (anthracyclines and related substances), ATC code: L01DB01.

Mechansim of action

The active ingredient of Caelyx is doxorubicin hydrochloride, a cytotoxic anthracycline antibiotic obtained from Streptomyces peucetius var. caesius. The exact mechanism of the antitumour activity of doxorubicin is not known. It is generally believed that inhibition of DNA, RNA and protein synthesis is responsible for the majority of the cytotoxic effects. This is probably the result of intercalation of the anthracycline between adjacent base pairs of the DNA double helix thus preventing their unwinding for replication.

Clinical efficacy and safety

A phase III randomised study of Caelyx versus doxorubicin in patients with metastatic breast cancer was completed in 509 patients. The protocol-specified objective of demonstrating non-inferiority between Caelyx and doxorubicin was met, the hazard ratio (HR) for progression-free survival (PFS) was 1.00 (95% CI for HR=0.82-1.22). The treatment HR for PFS when adjusted for prognostic variables was consistent with PFS for the ITT population.

The primary analysis of cardiac toxicity showed the risk of developing a cardiac event as a function of cumulative anthracycline dose was significantly lower with Caelyx than with doxorubicin (HR=3.16, p < 0.001). At cumulative doses greater than 450 mg/m2 there were no cardiac events with Caelyx.

A phase III comparative study of Caelyx versus topotecan in patients with epithelial ovarian cancer following the failure of first-line, platinum-based chemotherapy was completed in 474 patients. There was a benefit in overall survival (OS) for Caelyx-treated patients over topotecan-treated patients as indicated by a hazard ratio (HR) of 1.216 (95% CI: 1.000; 1.478), p=0.050. The survival rates at 1, 2 and 3 years were 56.3%, 34.7% and 20.2% respectively on Caelyx, compared to 54.0%, 23.6% and 13.2% on topotecan.

For the sub-group of patients with platinum-sensitive disease the difference was greater: HR of 1.432 (95% CI: 1.066; 1.923), p=0.017. The survival rates at 1, 2 and 3 years were 74.1%, 51.2% and 28.4% respectively on Caelyx, compared to 66.2%, 31.0% and 17.5% on topotecan.

The treatments were similar in the sub-group of patients with platinum-refractory disease: HR of 1.069 (95% CI: 0.823; 1.387), p=0.618. The survival rates at 1, 2 and 3 years were 41.5%, 21.1% and 13.8% respectively on Caelyx, compared to 43.2%, 17.2% and 9.5% on topotecan.

A phase III randomised, parallel-group, open-label, multicentre study comparing the safety and efficacy of Caelyx plus bortezomib combination therapy with bortezomib monotherapy in patients with multiple myeloma who have received at least 1 prior therapy and who did not progress while receiving anthracycline-based therapy, was conducted in 646 patients. There was a significant improvement in the primary endpoint of time to progression (TTP) for patients treated with combination therapy of Caelyx plus bortezomib compared to patients treated with bortezomib monotherapy as indicated by a risk reduction (RR) of 35% (95% CI: 21-47%), p < 0.0001, based on 407 TTP events. The median TTP was 6.9 months for the bortezomib monotherapy patients compared with 8.9 months for the Caelyx plus bortezomib combination therapy patients. A protocol-defined interim analysis (based on 249 TTP events) triggered early study termination for efficacy. This interim analysis showed a TTP risk reduction of 45% (95% CI: 29-57%), p < 0.0001. The median TTP was 6.5 months for the bortezomib monotherapy patients compared with 9.3 months for the Caelyx plus bortezomib combination therapy patients. These results, though not mature, constituted the protocol defined final analysis. The final analysis for overall survival (OS) performed after a median follow-up of 8.6 years showed no significant difference in OS between the two treatment arms. The median OS was 30.8 months (95% CI; 25.2-36.5 months) for the bortezomib monotherapy patients and

33.0 months (95% CI; 28.9-37.1 months) for the Caelyx plus bortezomib combination therapy patients.

5.2Pharmacokinetic properties

Caelyx is a long-circulating pegylated liposomal formulation of doxorubicin hydrochloride. Pegylated liposomes contain surface-grafted segments of the hydrophilic polymer methoxypolyethylene glycol (MPEG). These linear MPEG groups extend from the liposome surface creating a protective coating that reduces interactions between the lipid bilayer membrane and the plasma components. This allows the Caelyx liposomes to circulate for prolonged periods in the blood stream. Pegylated liposomes are small enough (average diameter of approximately 100 nm) to pass intact (extravasate) through defective blood vessels supplying tumours. Evidence of penetration of pegylated liposomes from blood vessels and their entry and accumulation in tumours has been seen in mice with C-26 colon carcinoma tumours and in transgenic mice with KS-like lesions. The pegylated liposomes also have a low permeability lipid matrix and internal aqueous buffer system that combine to keep doxorubicin hydrochloride encapsulated during liposome residence time in circulation.

The plasma pharmacokinetics of Caelyx in humans differ significantly from those reported in the literature for standard doxorubicin hydrochloride preparations. At lower doses (10 mg/m2–20 mg/m2) Caelyx displayed linear pharmacokinetics. Over the dose range of 10 mg/m2–60 mg/m2 Caelyx displayed non-linear pharmacokinetics. Standard doxorubicin hydrochloride displays extensive tissue distribution (volume of distribution: 700 to 1,100 l/m2) and a rapid elimination clearance (24 to

73 l/h/m2). In contrast, the pharmacokinetic profile of Caelyx indicates that Caelyx is confined mostly to the vascular fluid volume and that the clearance of doxorubicin from the blood is dependent upon the liposomal carrier. Doxorubicin becomes available after the liposomes are extravasated and enter the tissue compartment.

At equivalent doses, the plasma concentration and AUC values of Caelyx which represent mostly pegylated liposomal doxorubicin hydrochloride (containing 90% to 95% of the measured doxorubicin) are significantly higher than those achieved with standard doxorubicin hydrochloride preparations.

Caelyx should not be used interchangeably with other formulations of doxorubicin hydrochloride.

Population pharmacokinetics

The pharmacokinetics of Caelyx was evaluated in 120 patients from 10 different clinical trials using the population pharmacokinetic approach. The pharmacokinetics of Caelyx over the dose range of 10 mg/m2 to 60 mg/m2 was best described by a two compartment non-linear model with zero order

input and Michaelis-Menten elimination. The mean intrinsic clearance of Caelyx was 0.030 l/h/m2 (range 0.008 to 0.152 l/h/m2) and the mean central volume of distribution was 1.93 l/m2 (range 0.96-3.85 l/m2) approximating the plasma volume. The apparent half-life ranged from 24-231 hours, with a mean of 73.9 hours.

Breast cancer patients

The pharmacokinetics of Caelyx determined in 18 patients with breast carcinoma were similar to the pharmacokinetics determined in the larger population of 120 patients with various cancers. The mean intrinsic clearance was 0.016 l/h/m2 (range 0.008-0.027 l/h/m2), the mean central volume of distribution was 1.46 l/m2 (range 1.10-1.64 l/m2). The mean apparent half-life was 71.5 hours (range 45.2-98.5 hours).

Ovarian cancer patients

The pharmacokinetics of Caelyx determined in 11 patients with ovarian carcinoma were similar to the pharmacokinetics determined in the larger population of 120 patients with various cancers. The mean intrinsic clearance was 0.021 l/h/m2 (range 0.009–0.041 l/h/m2), the mean central volume of distribution was 1.95 l/m2 (range 1.67–2.40 l/m2). The mean apparent half-life was 75.0 hours (range 36.1–125 hours).

AIDS-related KS patients

The plasma pharmacokinetics of Caelyx were evaluated in 23 patients with KS who received single doses of 20 mg/m2 administered by a 30-minute infusion. The pharmacokinetic parameters of Caelyx (primarily representing pegylated liposomal doxorubicin hydrochloride and low levels of unencapsulated doxorubicin hydrochloride) observed after the 20 mg/m2 doses are presented in Table 10.

Table 10. Pharmacokinetic parameters in Caelyx-treated AIDS-KS patients

Mean + standard error

Parameter

20 mg/m2 (n=23)

Maximum plasma concentration* (µg/ml)

8.34

0.49

Plasma clearance (l/h/m2)

0.041

0.004

Volume of distribution (l/m2)

2.72 0.120

AUC (µg/ml h)

590.00 58.7

1 half-life (hours)

5.2

1.4

2 half-life (hours)

55.0 4.8

* Measured at the end of a 30-minute infusion

5.3Preclinical safety data

In repeat dose studies conducted in animals, the toxicity profile of Caelyx appears very similar to that reported in humans who receive long-term infusions of standard doxorubicin hydrochloride. With Caelyx, the encapsulation of doxorubicin hydrochloride in pegylated liposomes results in these effects having a differing strength, as follows.

Cardiotoxicity

Studies in rabbits have shown that the cardiotoxicity of Caelyx is reduced compared with conventional doxorubicin hydrochloride preparations.

Dermal toxicity

In studies performed after the repeated administration of Caelyx to rats and dogs, serious dermal inflammations and ulcer formations were observed at clinically relevant dosages. In the study in dogs, the occurrence and severity of these lesions was reduced by lowering the dose or prolonging the intervals between doses. Similar dermal lesions, which are described as palmar-plantar erythrodysesthesia were also observed in patients after long-term intravenous infusion (see section 4.8).

Anaphylactoid response

During repeat dose toxicology studies in dogs, an acute response characterised by hypotension, pale mucous membranes, salivation, emesis and periods of hyperactivity followed by hypoactivity and lethargy was observed following administration of pegylated liposomes (placebo). A similar, but less severe response was also noted in dogs treated with Caelyx and standard doxorubicin.

The hypotensive response was reduced in magnitude by pretreatment with antihistamines. However, the response was not life-threatening and the dogs recovered quickly upon discontinuation of treatment.

Local toxicity

Subcutaneous tolerance studies indicate that Caelyx, as against standard doxorubicin hydrochloride, causes slighter local irritation or damage to the tissue after a possible extravasation.

Mutagenicity and carcinogenicity

Although no studies have been conducted with Caelyx, doxorubicin hydrochloride, the pharmacologically active ingredient of Caelyx, is mutagenic and carcinogenic. Pegylated placebo liposomes are neither mutagenic nor genotoxic.

Reproductive toxicity

Caelyx resulted in mild to moderate ovarian and testicular atrophy in mice after a single dose of 36 mg/kg. Decreased testicular weights and hypospermia were present in rats after repeat doses0.25 mg/kg/day and diffuse degeneration of the seminiferous tubules and a marked decrease in spermatogenesis were observed in dogs after repeat doses of 1 mg/kg/day (see section 4.6).

Nephrotoxicity

A study has shown that Caelyx at a single intravenous dose of over twice the clinical dose produces renal toxicity in monkeys. Renal toxicity has been observed with even lower single doses of doxorubicin HCl in rats and rabbits. Since an evaluation of the post-marketing safety database for Caelyx in patients has not suggested a significant nephrotoxicity liability of Caelyx, these findings in monkeys may not have relevance to patient risk assessment.

6.PHARMACEUTICAL PARTICULARS

6.1List of excipients

-(2-[1,2-distearoyl-sn-glycero(3)phosphooxy]ethylcarbamoyl)- -methoxypoly(oxyethylen)-40 sodium salt (MPEG-DSPE)

fully hydrogenated soy phosphatidylcholine (HSPC) cholesterol

ammonium sulphate sucrose

histidine

water for injections hydrochloric acid sodium hydroxide

6.2Incompatibilities

This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.

6.3Shelf life

20 months.

After dilution:

-Chemical and physical in-use stability has been demonstrated for 24 hours at 2°C to 8°C.

-From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and should not be longer than 24 hours at 2°C to 8°C.

-Partially used vials must be discarded.

6.4Special precautions for storage

Store in a refrigerator (2°C - 8°C).

Do not freeze.

For storage conditions of the diluted medicinal product, see section 6.3.

6.5Nature and contents of container

Type I glass vials, each with a siliconised grey bromobutyl stopper, and an aluminium seal, with a deliverable volume of 10 ml (20 mg) or 25 ml (50 mg).

Caelyx is supplied as a single pack or packs of ten vials.

Not all pack sizes may be marketed.

6.6Special precautions for disposal and other handling

Do not use material that shows evidence of precipitation or any other particulate matter.

Caution must be exercised in handling Caelyx solution. The use of gloves is required. If Caelyx comes into contact with skin or mucosa, wash immediately and thoroughly with soap and water. Caelyx must be handled and disposed of in a manner consistent with that of other anticancer medicinal products in accordance with local requirements.

Determine the dose of Caelyx to be administered (based upon the recommended dose and the patient’s body surface area). Take the appropriate volume of Caelyx up into a sterile syringe. Aseptic technique must be strictly observed since no preservative or bacteriostatic agent is present in Caelyx. The appropriate dose of Caelyx must be diluted in 5% (50 mg/ml) glucose solution for infusion prior to administration. For doses < 90 mg, dilute Caelyx in 250 ml, and for doses 90 mg, dilute Caelyx in 500 ml. This can be infused over 60 or 90 minutes as detailed in 4.2.

The use of any diluent other than 5% (50 mg/ml) glucose solution for infusion, or the presence of any bacteriostatic agent such as benzyl alcohol may cause precipitation of Caelyx.

It is recommended that the Caelyx infusion line be connected through the side port of an intravenous infusion of 5% (50 mg/ml) glucose. Infusion may be given through a peripheral vein. Do not use with in-line filters.

7.MARKETING AUTHORISATION HOLDER

Janssen-Cilag International NV

Turnhoutseweg 30

B-2340 Beerse

Belgium

8.MARKETING AUTHORISATION NUMBER(S)

EU/1/96/011/001

EU/1/96/011/002

EU/1/96/011/003

EU/1/96/011/004

9.DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 21 June 1996

Date of lastest renewal: 19 May 2006

10.DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http://www.ema.europa.eu/.

Comments

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
  • Help
  • Get it on Google Play
  • About
  • Info on site by:

  • Presented by RXed.eu

  • 27558

    prescription drugs listed